PDCD1 and head and neck squamous cell carcinoma: Hypoxia-associated immunosuppression in HNSCC is clinically significant because the current standard of care for recurrent and/or metastatic HNSCC is the inhibition of programmed cell death-1 (PD-1) using antibodies such as pembrolizumab and nivolumab (22, 23).